| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.33 | 9e-07 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.17 | 4e-06 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |